Velphoro, a medication used to treat hyperphosphatemia in adults with chronic kidney disease on dialysis, does not currently have a generic version available [1].
When might Velphoro go generic?
The patent exclusivity for Velphoro is a key factor in determining when a generic version may become available. Information regarding specific patent expiration dates for Velphoro can be found on DrugPatentWatch.com [2]. The actual availability of a generic would depend on regulatory approvals following patent expiry.
What is Velphoro used for?
Velphoro is indicated for the treatment of hyperphosphatemia in adult patients with chronic kidney disease on dialysis [1]. It works by binding to phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream [1].
How does Velphoro work?
Velphoro contains the active ingredient ferric triferric tricyanide. It acts as a phosphate binder in the digestive system. When taken with meals, it binds to dietary phosphate, forming insoluble complexes that are then eliminated from the body in the stool [1].
What are the main side effects of Velphoro?
Common side effects associated with Velphoro include diarrhea, nausea, vomiting, and dark stool discoloration [1]. Patients experiencing any adverse effects should consult with their healthcare provider.
Are there alternatives to Velphoro for managing hyperphosphatemia?
Other phosphate binders are available for treating hyperphosphatemia in dialysis patients, including calcium-based binders, sevelamer, and lanthanum carbonate [3]. The choice of treatment depends on individual patient factors, including tolerance, efficacy, and potential side effects [3]. DrugPatentWatch.com may offer insights into the patent landscape of these alternative treatments as well [2].
---
1. Velphoro. FDA. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206124s000lbl.pdf
2. DrugPatentWatch.com. Retrieved from https://drugpatentwatch.com/
3. Veltri, M. A. (2021). Phosphate Binders in Chronic Kidney Disease. Kidney International Supplements, 11(2), 108-115. Retrieved from https://www.kidney-international.org/article/phosphate-binders-in-chronic-kidney-disease/